🧬🚀 Latest breakthroughs in oncology research!
🏥✨ From innovative trial results to global regulatory milestones across a wide range of cancer types, this week’s roundup delivers the insights that matter.
Explore how AFM24 is reshaping non-small cell lung cancer outcomes, why Phesgo is poised to transform HER2-positive care at home, and how emerging therapies like INX-315 and Tepylute are addressing unmet needs in ovarian and breast cancers. 🏥✨
We cover pivotal clinical data, first-in-class approvals, and global trial expansions—all in one concise update. 🌍 Whether you’re following developments in gastric, prostate, esophageal, or bladder cancer, this is your trusted source. 🎯
🔎 Key Highlights:
💥 AFM24 boosts ORR from 5.6 to 33.3 percent and extends PFS to 7.3 months in NSCLC patients with higher exposure.
🧪 SC-101 receives FDA Orphan Drug Designation for esophageal cancer, unlocking regulatory incentives.
🌍 NERLYNX® expands access across 10+ Eastern European countries through Puma and Er-Kim partnership.
🏡 CHMP supports at-home subcutaneous administration of Phesgo for HER2-positive breast cancer, with 85 percent patient preference and up to 80 percent cost savings.
💉 Tepylute becomes the first FDA-approved stable multi-dose formulation of thiotepa for breast and ovarian cancers.
🇪🇺 Henlius gains EU clearance for a Phase 3 trial targeting HER2-positive gastric cancer.
🧬 Kura Oncology initiates GIST combination trial with ziftomenib and imatinib based on strong preclinical synergy.
🚀 INX-315 receives FDA Fast Track for platinum-resistant, CCNE1-amplified ovarian cancer.
❌ AstraZeneca halts Truqap + docetaxel trial in mCRPC after failing to meet efficacy endpoints.
📉 Bayer’s darolutamide plus ADT achieves ultra-low PSA in over 42 percent of patients, tied to improved PFS and delayed metastasis.
🌍 enGene expands pivotal bladder cancer gene therapy trial across five major European countries.
⏱️ BMS earns UK approval for subcutaneous Opdivo, cutting infusion time from 60 to just 5 minutes.
📢 Stay Ahead in Oncology Research!
✅ Like, share, and subscribe for weekly updates on oncology and breakthrough cancer therapies.
#OncologyUpdates #CancerResearch #NSCLC #HER2Positive #OvarianCancer #ClinicalTrials #FDAApprovals #TargetedTherapy #BladderCancer #ProstateCancer #LucidQuest #HealthcareInnovation #LQVentures